Fineline Cube

Follow:
14422 Articles
Sinclair’s MaiLi Precise Receives NMPA Acceptance Notice for Class III Device
CompanyMedical Device

Sinclair’s MaiLi Precise Receives NMPA Acceptance Notice for Class III Device

I‑Mab Announces Global Transformation, NovaBridge Rebranding, and $37 M Acquisition of VIS‑101
CompanyDeals

I‑Mab Announces Global Transformation, NovaBridge Rebranding, and $37 M Acquisition of VIS‑101

CStone’s Sugemalimab Receives Positive EMA Opinion for Stage III NSCLC
CompanyDrug

CStone’s Sugemalimab Receives Positive EMA Opinion for Stage III NSCLC

Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia
CompanyDeals

Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia

Gan & Lee Pharma, Fiocruz Sign MoU to Advance GZR4 and GZR102 Insulin Candidates
CompanyDeals

Gan & Lee Pharma, Fiocruz Sign MoU to Advance GZR4 and GZR102 Insulin Candidates

Hansoh Pharma Grants Roche Exclusive Global Rights to CDH17‑Targeting ADC HS‑20110
CompanyDeals

Hansoh Pharma Grants Roche Exclusive Global Rights to CDH17‑Targeting ADC HS‑20110

Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase II/III Trial
CompanyDrug

Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase II/III Trial

AstraZeneca China Integrates Symbicort and Breztri Sales Teams in New Organizational Shake‑Up
Company

AstraZeneca China Integrates Symbicort and Breztri Sales Teams in New Organizational Shake‑Up

Leads Biolabs, Dianthus Therapeutics Announce Global Partnership for LBL‑047 Bispecific Fusion Protein
CompanyDeals

Leads Biolabs, Dianthus Therapeutics Announce Global Partnership for LBL‑047 Bispecific Fusion Protein

NeuroGen Pharma Secures Exclusive Rights to Brexpiprazole Orally Disintegrating Film from Bocimed
CompanyDeals

NeuroGen Pharma Secures Exclusive Rights to Brexpiprazole Orally Disintegrating Film from Bocimed

Chia Tai Tianqing Secures NMPA Approval for Phase III Trial of TQB2868 + Anlotinib in First‑Line mPDAC Therapy
CompanyDrug

Chia Tai Tianqing Secures NMPA Approval for Phase III Trial of TQB2868 + Anlotinib in First‑Line mPDAC Therapy

Lepu Biopharma Enrolls First Patient in Phase II Trial of MRG006A, the World’s First GPC3‑Targeting ADC
CompanyDrug

Lepu Biopharma Enrolls First Patient in Phase II Trial of MRG006A, the World’s First GPC3‑Targeting ADC